查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844119

上游生物加工市場（按產品、技術、應用、最終用戶、規模和細胞類型）—2025-2032 年全球預測

Upstream Bioprocessing Market by Product, Technology, Application, End User, Scale, Cell Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，上游生物加工市場將成長至 345.1 億美元，複合年成長率為 13.99%。

主要市場統計數據
基準年2024年 120.9億美元
預計2025年 138.1億美元
預測年份：2032年 345.1億美元
複合年成長率（%） 13.99%

為決策者提供上游生物製程基本面、融合技術促進因素、監管期望和營運重點的簡明策略方向

上游生物製程是現代生技藥品製造的核心，它融合了細胞培養、培養基設計、反應器工程和製程分析，以提供安全有效的治療方法。細胞系工程和一次性技術的進步正在重新定義企業如何應對可擴展性、製程靈活性和臨床上市時間的限制。同時，監管要求和供應鏈現狀也日益凸顯了上游工作流程中穩健性、可追溯性和可重複性的重要性。

本介紹總結了影響學術、工業和合約研究環境中策略和投資的關鍵促進因素。它闡述了影響製程結果的產品和技術選擇之間的相互作用，強調了培養基和試劑最佳化對細胞健康和生產力日益成長的重要性，並概述了一次性和不銹鋼基礎設施之間不斷變化的平衡。本觀點旨在幫助企業主管和技術領導者了解平台選擇、供應商合作夥伴關係和生產力計畫等決策背後的當務之急和結構性權衡。

本部分將揭示創新、監管和營運約束之間的聯繫，為深入探討後續轉型變化、資費影響、細分洞察、區域動態和競爭影響奠定基礎。讀者將獲得基於實證的實用依據，以評估應將資源集中於何處，從而在管理商業性風險的同時保持技術競爭力。

模組化一次性使用、培養基最佳化、先進感測器和嚴格的法規如何改變上游生物加工策略和營運模式

上游生物製程環境正在經歷一場變革，其驅動力在於技術整合、模組化以及對臨床驗證速度的日益重視。一次性設備的加速普及使得設施佈局更加靈活，宣傳活動週期也更加快速，而感測器技術和即時分析技術的進步則使得製程控制更加嚴格，批次差異性也得以降低。同時，從攪拌槽到氣升反應器再到波浪式生物反應器等各種反應器類型的出現，使企業能夠根據產品屬性和生產規模來客製化生物製程架構，從而實現更精準的技術選擇。

同時，培養基和試劑科學正在從現成的配方發展到高度最佳化、化學成分明確的配方，以支持更高的滴度和更穩定的產品品質。這種轉變減少了對動物性成分的依賴，簡化了監管文件，但也對供應鏈的彈性和供應商合格提出了新的要求。同時，細胞和基因療法的發展正在再形成應用優先級，推動向更短的生產週期、分散的生產模式和封閉式系統加工的轉變，以控制無菌性和可追溯性。

監管動態強化了對穩健的製程表徵和控制策略的需求，推動了對製程分析技術和模擬放大行為的數位雙胞胎的投資。隨著企業尋求加快產品上市速度並共擔風險，設備供應商、培養基配方商和契約製造製造商之間的策略聯盟正變得越來越普遍。如今，靈活、分析性和可互通的實驗室到生產工作流程與原始加工能力一樣，決定著競爭優勢。

評估不斷變化的關稅政策如何推動上游生物加工供應鏈中的供應商多樣化、總體擁有成本分析和應急策略

2025年前美國關稅格局的不斷演變，為上游生物加工供應基地的供應鏈規劃、籌資策略和供應商談判增添了額外的複雜性。關稅調整會影響關鍵投入的到岸成本，例如專用一次性組件、感測器、探針和某些試劑類別，迫使採購和營運團隊重新評估採購區域、庫存緩衝和資格認證時間表。為此，許多公司正在平衡短期成本壓力與供應商多元化和冗餘的策略價值，以保障生產的連續性。

製造商和合約組織擴大評估總體擁有成本，而不僅僅是單位成本，同時將物流前置作業時間、關稅徵收機制以及關稅分類和合規的行政管理費用納入考慮。一些技術團隊優先考慮模組化、可互通的系統，以便從其他供應商進行零件交換，同時最大限度地減少重新驗證的負擔。同時，延長新供應商的資格認證週期可以加快技術轉移通訊協定和標準化驗收標準的製定，從而減輕引入其他供應商的干擾。

政策的不確定性也增加了供應商協作和合約彈性的重要性。各機構正在協商的條款包括對沖條款、雙重採購承諾以及關鍵試劑和一次性組件的緊急庫存。供應鏈、品質和製程開發之間的跨職能協作至關重要，它能將關稅帶來的風險轉化為提升製程穩健性、改善供應商績效指標和策略性庫存管理的機會，從而防止臨床和商業生產中斷。

將產品系列、反應器技術、應用、最終用戶、規模和電池類型聯繫起來的詳細細分分析，為有針對性的投資和工藝調整策略提供資訊

細分分析揭示了投資、創新和營運重點在產品、技術、應用、最終用戶、規模和細胞類型維度上的融合點。按產品分類，涵蓋配件和耗材、生物反應器、培養基和試劑、感測器和探針以及一次性設備。在培養基和試劑方面，分析重點在於基礎培養基、化學成分確定的培養基、無血清培養基、緩衝液和鹽、細胞培養補充劑和生長因子，重點是配方選擇如何影響細胞性能和監管透明度。按技術分類，氣升、固定台、一次性、攪拌槽式和波式在剪切環境、氧轉移和規模軌跡方面提供互補的權衡，使製程開發人員能夠選擇滿足其細胞生物學和通量需求的架構。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 利用人工智慧和機器學習演算法實現上游生物加工的即時製程控制和最佳化
  • 實施連續灌注策略以提高細胞密度產量，同時減少生物製造中的生產足跡
  • 整合數位雙胞胎技術，用於細胞培養過程早期階段的預測建模和虛擬放大
  • 推出先進的、整合感測器的一次性生物反應器系統，用於靈活的分散式製造操作
  • 利用基於 CRISPR 的基因組編輯技術開發基因工程細胞株，以最佳化蛋白質表現和代謝穩定性
  • 應用基於體學的培養基最佳化和餵養策略來改善細胞生長和目標蛋白質品質屬性
  • 引入線上拉曼和紅外線光譜技術，即時監測發酵過程中的關鍵程式參數
  • 專注於透過高細胞密度灌注培養來強化工藝，以提高體積生產率和成本效率。
  • 利用綠色化學原理和可再生原料來促進永續和環保的上游工程
  • 透過分散式模組化設施的整合，加速臨床製造並最大限度地縮短技術轉移時間。

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章上游生物加工市場（按產品）

  • 配件和耗材
  • 生物反應器
  • 培養基和試劑
    • 媒體
      • 基礎培養基
      • 化學成分確定的培養基
      • 無血清培養基
    • 試劑
      • 緩衝液和鹽
      • 細胞培養補充劑
      • 生長因子
  • 感測器和探頭
  • 免洗設備

9. 上游生物加工市場（依技術）

  • 氣升生物反應器
  • 固定台生物反應器
  • 免洗生物反應器
  • 攪拌槽生物反應器
  • 波浪生物反應器

第 10 章上游生物加工市場（依應用）

  • 細胞治療製造
  • 基因治療載體製造
  • 單株抗體生產
  • 重組蛋白生產
  • 疫苗生產

第 11 章。上游生物加工市場（依最終用戶）

  • 學術研究機構
  • 生物製藥公司
  • 合約研究組織
  • 政府研究機構

第12章上游生物加工市場規模

  • 實驗室規模
  • 大規模
  • 中試規模

13. 上游生物加工市場（依細胞類型）

  • 昆蟲細胞培養
  • 哺乳動物細胞培養
  • 微生物發酵
  • 植物細胞培養

十四章上游生物加工市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章上游生物加工市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 上游生物處理市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Sartorius AG
    • Merck KGaA
    • Lonza Group AG
    • Corning Incorporated
    • Eppendorf AG
    • Bio-Rad Laboratories, Inc.
    • Repligen Corporation
    • Takara Bio Inc.
Product Code: MRR-A26E0E574508

The Upstream Bioprocessing Market is projected to grow by USD 34.51 billion at a CAGR of 13.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.09 billion
Estimated Year [2025] USD 13.81 billion
Forecast Year [2032] USD 34.51 billion
CAGR (%) 13.99%

A concise strategic orientation to upstream bioprocessing fundamentals, converging technological drivers, regulatory expectations, and operational priorities for decision-makers

Upstream bioprocessing sits at the heart of modern biologics production, where cell culture, media design, reactor engineering, and process analytics converge to deliver safe and effective therapies. Advances in cell-line engineering and single-use technologies are redefining how organizations approach scalability, process flexibility, and time-to-clinic constraints. At the same time, regulatory expectations and supply chain realities are increasing the premium placed on robustness, traceability, and reproducibility across the upstream workflow.

This introduction synthesizes the primary drivers shaping strategy and investment across academic, industrial, and contract research environments. It frames the interplay between product and technology choices that influence process outcomes, highlights the rising importance of media and reagent optimization for cell health and productivity, and profiles the shifting balance between single-use and stainless-steel infrastructures. The perspective aims to orient executives and technical leads to the immediate priorities and structural trade-offs that underpin decisions about platform selection, supplier partnerships, and capacity planning.

By clarifying the nexus of innovation, regulation, and operational constraints, this section sets the stage for a deeper examination of the transformative shifts, tariff impacts, segmentation insights, regional dynamics, and competitive implications that follow. Readers will gain a pragmatic, evidence-based foundation for assessing where to concentrate resources to maintain technical competitiveness while managing commercial risk.

How modular single-use adoption, media optimization, advanced sensors, and regulatory rigor are reshaping upstream bioprocessing strategies and operational models

The upstream bioprocessing landscape is undergoing transformative shifts driven by technological integration, modularization, and a heightened focus on speed to clinical validation. Single-use equipment adoption has accelerated, enabling more flexible facility footprints and rapid campaign turnovers, while advances in sensor technology and real-time analytics are enabling tighter process control and reduced batch variability. Meanwhile, diverse reactor formats-ranging from stirred-tank to airlift and wave bioreactors-allow organizations to match bioprocess architecture to product attributes and production scale, creating a more nuanced technology selection calculus.

Concurrently, media and reagent science is evolving from off-the-shelf formulations toward highly optimized, chemically defined compositions that support higher titers and more consistent product quality. This shift reduces reliance on animal-derived components and simplifies regulatory dossiers, but it also places new demands on supply chain resilience and vendor qualification. In parallel, the growth of cell and gene therapies is reshaping application priorities, with a move toward shorter production runs, decentralized manufacturing models, and closed-system processing to manage sterility and traceability.

Regulatory dynamics are reinforcing the need for robust process characterization and control strategies, driving investment in process analytical technologies and digital twins that simulate scale-up behavior. Strategic partnerships between equipment providers, media formulators, and contract manufacturers are becoming more common as organizations seek to accelerate time-to-market while sharing risk. Taken together, these shifts are redefining the upstream playbook: flexibility, analytics, and interoperable lab-to-production workflows now determine competitive advantage as much as raw throughput.

Assessing how shifting tariff policies are prompting supplier diversification, total cost of ownership analysis, and contingency strategies within upstream bioprocessing supply chains

The evolving tariff landscape in the United States for 2025 has introduced additional layers of complexity for supply chain planning, procurement strategies, and supplier negotiations across the upstream bioprocessing supply base. Tariff adjustments influence the landed cost of key inputs such as specialized single-use components, sensors, probes, and certain reagent categories-forcing procurement and operations teams to re-evaluate sourcing geographies, inventory buffers, and qualification timelines. In response, many organizations are balancing near-term cost pressures with the strategic value of supplier diversification and redundancy to protect production continuity.

Manufacturers and contract organizations are increasingly assessing the total cost of ownership rather than unit price alone, factoring in logistics lead times, duty recovery mechanisms, and the administrative overhead of customs classification and compliance. Some technical teams are prioritizing modular and interoperable systems that allow substitution of components from alternative suppliers with minimal revalidation burden. At the same time, longer qualification cycles for new suppliers can be used to accelerate technical transfer protocols and standardized acceptance criteria that mitigate disruption when alternative sources are engaged.

Policy uncertainty has also heightened the importance of collaborative supplier relationships and contractual flexibility. Organizations are negotiating terms that include hedging provisions, dual-sourcing commitments, and contingency stocks for critical reagents and single-use assemblies. Cross-functional alignment between supply chain, quality, and process development is essential to convert tariff-driven risk into opportunities for process robustness, better supplier performance metrics, and strategic inventory management that supports uninterrupted clinical and commercial manufacturing.

In-depth segmentation analysis linking product portfolios, reactor technologies, applications, end users, scales, and cell types to inform targeted investment and process alignment strategies

Segmentation analysis reveals where investment, innovation, and operational focus converge across product, technology, application, end user, scale, and cell type dimensions. Based on product, the landscape spans accessories and consumables, bioreactors, media and reagents, sensors and probes, and single-use equipment; within media and reagents, distinct attention to basal media, chemically defined media, and serum-free options, along with buffers and salts, cell culture supplements, and growth factors, highlights how formulation choices drive cell performance and regulatory clarity. Based on technology, airlift, fixed-bed, single-use, stirred-tank, and wave formats present complementary trade-offs in shear environment, oxygen transfer, and scale trajectories, enabling process developers to select architectures that match cell biology and throughput needs.

Based on application, different product classes impose divergent upstream constraints: cell therapy production demands closed, low-volume, high-assurance workflows with rapid turnaround; gene therapy vector production emphasizes high-purity, scalable processes and stringent analytics; monoclonal antibody and recombinant protein production prioritize titer optimization, consistent glycosylation profiles, and long-term operational stability; vaccine production emphasizes robust yield and rapid surge capacity for public health responses. Based on end user, academic and research institutes focus on platform flexibility and cost-efficiency for exploratory work, biopharmaceutical companies require validated, scalable systems for late-stage development, contract research and manufacturing organizations emphasize throughput, interoperability, and standardized handover procedures, while government laboratories prioritize reproducibility and compliance for surveillance and biodefense applications.

Based on scale, lab-scale systems prioritize flexibility and rapid iteration; pilot-scale infrastructure bridges development and production risk assessment; large-scale operations demand rigorous process control, component robustness, and lifecycle cost management. Based on cell type, insect, mammalian, microbial, and plant cell culture systems introduce different requirements for media composition, bioreactor design, and downstream interface strategies. Understanding these segmentation intersections enables leaders to align technology adoption with application-specific performance metrics and to design procurement and quality frameworks that reduce downstream rework during scale-up transitions.

How regional supply chain architectures, regulatory cultures, and capacity expansion trends across major geographies influence upstream bioprocessing deployment and resilience

Regional dynamics shape supply chain design, regulatory alignment, and strategic deployment of capacity across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, strong biopharmaceutical hubs and an established contract manufacturing base support rapid clinical and commercial scale-up, with emphasis on agile single-use deployments, process intensification, and a regulatory environment that encourages innovation balanced with strict quality standards. Supply chains in this region are increasingly focused on regional sourcing and expedited logistics to reduce exposure to cross-border tariff and transit volatility, while academic-industrial partnerships continue to drive translational pipelines.

In Europe, the Middle East & Africa, regulatory harmonization efforts and integrated supplier ecosystems favor advanced process control adoption and stringent compliance frameworks. European centers of excellence maintain depth in sensor innovation, cell-line engineering, and media formulation expertise, which supports a strong manufacturing ecosystem for complex biologics. Meanwhile, regulatory expectations for documentation and traceability encourage investments in digital batch records and vendor qualification frameworks that can serve multinational operations.

Asia-Pacific is characterized by rapid capacity expansion, a growing base of contract manufacturers, and a strategic focus on lowering cost-per-dose for regionally important therapeutics and vaccines. The region is seeing accelerated adoption of scalable single-use solutions and investments in workforce training to support novel modalities. Cross-border partnerships and regional hubs for reagent and consumable manufacturing are emerging to shorten lead times and enable localized resilience. The interplay across these regions informs decisions about where to place development sites, how to structure supplier contracts, and which process architectures are best suited to meet global distribution and regulatory requirements.

Competitive landscape insights highlighting how technical depth, integrated services, digital enablement, and supply resilience are differentiating upstream bioprocessing vendors

Competitive dynamics among suppliers reflect a balance between platform breadth, depth of technical support, and the ability to integrate into customer development workflows. Leading equipment and consumable providers are differentiating through modular, interoperable product lines that reduce validation burdens and accelerate technical transfer. These players also emphasize strong application support, offering process development services, analytics suites, and collaborative engineering to help customers achieve predictable scale-up and consistent product quality. Investment in digital enablement-such as cloud-based process monitoring, predictive maintenance analytics, and digital twin capabilities-has become a distinguishing capability for technology providers seeking long-term strategic partnerships.

Suppliers who excel in media and reagent science are focusing on chemically defined formulations and stability improvements that support higher cell densities and lower lot-to-lot variability. Strategic moves include co-development agreements with cell-line companies and integrations that bundle media with guidance on feeding strategies and analytics. Component and consumable manufacturers are streamlining supply chains, expanding regional warehousing, and offering vendor-managed inventory options to reduce interruption risks. Contract manufacturers and service providers are enhancing their propositions by offering end-to-end solutions that include process development, quality transfer, and multi-site manufacturing networks, enabling customers to outsource complexity while retaining control over product quality attributes.

Competitive advantage will increasingly accrue to firms that can combine deep technical knowledge, robust regulatory support, and an ecosystem approach that integrates equipment, consumables, and digital services. Companies that invest in transparent performance data, reproducible validation packages, and flexible commercial models are better positioned to capture long-term relationships with both emerging therapy developers and established biopharmaceutical manufacturers.

Actionable strategic imperatives for executives to optimize modular flexibility, analytics-driven control, dual-sourcing resilience, and workforce readiness across upstream operations

Industry leaders should prioritize modular flexibility, analytics integration, and supply chain resilience to maintain competitive advantage and operational continuity. Investing in interoperable single-use systems and standardized interfaces reduces revalidation timelines during supplier substitution while enabling rapid scale-up campaigns for clinical and commercial production. Simultaneously, embedding advanced sensors and process analytical technologies within development and production workflows will shorten characterization cycles and support quality-by-design approaches that facilitate regulatory interactions.

Procurement and quality teams should establish strategic dual-sourcing relationships for critical items such as media, growth factors, and proprietary single-use components, and negotiate contractual mechanisms that allow for surge capacity and price stability. Cross-functional governance structures that align R&D, manufacturing, quality, and procurement are essential for coherent decision-making around vendor qualification and process changes. Leaders should also consider investing in digital infrastructure for real-time inventory visibility, predictive reorder triggers, and analytics that flag supply anomalies before they impact campaigns.

From a technology roadmap perspective, organizations should evaluate reactor architectures against specific application needs and cell biology, favoring platforms that support closed processing and rapid cleaning/turnaround where sterility and contamination control are paramount. Finally, develop targeted training and knowledge-transfer programs to ensure operators and scientists can effectively manage new technologies and protocols, thereby reducing human-error risk and accelerating the time from process development to reliable production.

A rigorous mixed-methods approach combining primary expert interviews, technical benchmarking, literature synthesis, and scenario analysis to validate upstream bioprocessing insights

The research methodology underpinning this analysis combined systematic literature synthesis, technology benchmarking, and qualitative expert engagement to build a holistic view of upstream bioprocessing trends and operational considerations. Primary inputs included structured interviews with process development scientists, manufacturing leads, quality assurance professionals, and supply chain managers to capture first-hand perspectives on technology performance, supplier relationships, and operational constraints. These insights were complemented by direct device and formulation evaluations, where technical attributes such as mixing dynamics, oxygen transfer characteristics, and sensor compatibility were assessed against application-specific requirements.

Secondary research involved critical review of peer-reviewed publications, regulatory guidance documents, and publicly available technical whitepapers to validate claims regarding media performance, reactor behavior, and analytics maturity. Cross-validation steps ensured that anecdotal observations from primary interviews were examined against documented experimental results and manufacturer technical specifications. The methodology also incorporated scenario-based analysis to assess how changes in tariffs, supplier availability, or regulatory expectations could influence procurement and operational choices.

To ensure rigor, the approach emphasized triangulation across multiple data sources, transparent documentation of assumptions, and engagement with subject matter experts to test interpretations. Wherever possible, technical assertions were grounded in reproducible evidence and in the context of typical development-to-manufacturing pathways, recognizing variability across cell types, applications, and regional regulatory frameworks.

Concluding synthesis affirming that technology integration, media optimization, and supply chain resilience collectively determine operational agility and product quality in upstream bioprocessing

This executive synthesis underscores that upstream bioprocessing is at an inflection point where technology selection, media science, and supply chain strategy collectively determine program velocity and product quality. The transition to modular single-use systems, the adoption of chemically defined media, and the integration of advanced analytics are not isolated trends; they form an interdependent ecosystem that enables reproducible scale-up, regulatory compliance, and rapid response to demand surges. Organizations that align process development objectives with procurement and quality frameworks will more effectively translate laboratory gains into manufacturing reliability.

Geopolitical and policy developments that affect tariffs and cross-border flows introduce new operational considerations but also create strategic opportunities to build regional supply resiliency and supplier partnerships. Segmentation analysis highlights that technology and product choices must be tailored to application-specific needs-from the closed-system demands of cell therapy to the throughput pressures of vaccine production-while regional differences inform where and how capacity should be deployed. Ultimately, sustained competitive advantage will accrue to teams that can integrate technical excellence with agile supplier strategies, robust digital capabilities, and a skilled workforce prepared to manage increasingly sophisticated upstream processes.

Leaders should view investment in interoperable platforms, analytics, and supplier ecosystems not just as cost centers, but as strategic enablers that reduce time-to-clinic, improve product quality consistency, and enhance organizational resilience in the face of evolving operational risks.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of artificial intelligence and machine learning algorithms for real-time process control and optimization in upstream bioprocessing
  • 5.2. Implementation of continuous perfusion strategies to increase cell density yield while reducing production footprints in biomanufacturing
  • 5.3. Integration of digital twin technology for predictive modeling and virtual scale-up of early stage cell culture processes
  • 5.4. Adoption of single-use bioreactor systems with advanced sensor integration for flexible decentralized manufacturing operations
  • 5.5. Development of engineered cell lines using CRISPR based genome editing for optimized protein expression and metabolic stability
  • 5.6. Application of omics-driven media optimization and feed strategies to enhance cell growth and target protein quality attributes
  • 5.7. Deployment of inline Raman and near-infrared spectroscopy for real-time monitoring of critical process parameters in fermentation
  • 5.8. Focus on process intensification through high cell density perfusion cultures to improve volumetric productivity and cost efficiency
  • 5.9. Use of green chemistry principles and renewable raw materials to promote sustainable and eco-friendly upstream processes
  • 5.10. Integration of decentralized modular facilities to accelerate clinical manufacturing and minimize technology transfer timelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Upstream Bioprocessing Market, by Product

  • 8.1. Accessories And Consumables
  • 8.2. Bioreactors
  • 8.3. Media And Reagents
    • 8.3.1. Media
      • 8.3.1.1. Basal Media
      • 8.3.1.2. Chemically Defined Media
      • 8.3.1.3. Serum-Free Media
    • 8.3.2. Reagents
      • 8.3.2.1. Buffers And Salts
      • 8.3.2.2. Cell Culture Supplements
      • 8.3.2.3. Growth Factors
  • 8.4. Sensors And Probes
  • 8.5. Single-Use Equipment

9. Upstream Bioprocessing Market, by Technology

  • 9.1. Airlift Bioreactors
  • 9.2. Fixed-Bed Bioreactors
  • 9.3. Single-Use Bioreactors
  • 9.4. Stirred-Tank Bioreactors
  • 9.5. Wave Bioreactors

10. Upstream Bioprocessing Market, by Application

  • 10.1. Cell Therapy Production
  • 10.2. Gene Therapy Vector Production
  • 10.3. Monoclonal Antibody Production
  • 10.4. Recombinant Protein Production
  • 10.5. Vaccine Production

11. Upstream Bioprocessing Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Biopharmaceutical Companies
  • 11.3. Contract Research Organizations
  • 11.4. Government Laboratories

12. Upstream Bioprocessing Market, by Scale

  • 12.1. Lab Scale
  • 12.2. Large Scale
  • 12.3. Pilot Scale

13. Upstream Bioprocessing Market, by Cell Type

  • 13.1. Insect Cell Culture
  • 13.2. Mammalian Cell Culture
  • 13.3. Microbial Fermentation
  • 13.4. Plant Cell Culture

14. Upstream Bioprocessing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Upstream Bioprocessing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Upstream Bioprocessing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. Danaher Corporation
    • 17.3.3. Sartorius AG
    • 17.3.4. Merck KGaA
    • 17.3.5. Lonza Group AG
    • 17.3.6. Corning Incorporated
    • 17.3.7. Eppendorf AG
    • 17.3.8. Bio-Rad Laboratories, Inc.
    • 17.3.9. Repligen Corporation
    • 17.3.10. Takara Bio Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SCALE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SCALE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. UPSTREAM BIOPROCESSING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. UPSTREAM BIOPROCESSING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. UPSTREAM BIOPROCESSING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACCESSORIES AND CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BASAL MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BASAL MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BASAL MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BASAL MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BASAL MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BASAL MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CHEMICALLY DEFINED MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CHEMICALLY DEFINED MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CHEMICALLY DEFINED MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CHEMICALLY DEFINED MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CHEMICALLY DEFINED MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CHEMICALLY DEFINED MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SERUM-FREE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SERUM-FREE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SERUM-FREE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SERUM-FREE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SERUM-FREE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SERUM-FREE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BUFFERS AND SALTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BUFFERS AND SALTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BUFFERS AND SALTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BUFFERS AND SALTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BUFFERS AND SALTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BUFFERS AND SALTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL CULTURE SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL CULTURE SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL CULTURE SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL CULTURE SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL CULTURE SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL CULTURE SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SENSORS AND PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SENSORS AND PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SENSORS AND PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SENSORS AND PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SENSORS AND PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SENSORS AND PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY AIRLIFT BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY AIRLIFT BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY AIRLIFT BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY AIRLIFT BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY AIRLIFT BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY AIRLIFT BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY FIXED-BED BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY FIXED-BED BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY FIXED-BED BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY FIXED-BED BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY FIXED-BED BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY FIXED-BED BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY STIRRED-TANK BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY STIRRED-TANK BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY STIRRED-TANK BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY STIRRED-TANK BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY STIRRED-TANK BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY STIRRED-TANK BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY WAVE BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY WAVE BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY WAVE BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY WAVE BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY WAVE BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY WAVE BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL THERAPY PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL THERAPY PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL THERAPY PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL THERAPY PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL THERAPY PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL THERAPY PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GENE THERAPY VECTOR PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GENE THERAPY VECTOR PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GENE THERAPY VECTOR PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GENE THERAPY VECTOR PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GENE THERAPY VECTOR PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GENE THERAPY VECTOR PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODY PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODY PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODY PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODY PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODY PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY RECOMBINANT PROTEIN PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY RECOMBINANT PROTEIN PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY RECOMBINANT PROTEIN PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY RECOMBINANT PROTEIN PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY RECOMBINANT PROTEIN PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY RECOMBINANT PROTEIN PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GOVERNMENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GOVERNMENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GOVERNMENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GOVERNMENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GOVERNMENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY GOVERNMENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LAB SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LAB SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LAB SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LAB SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LAB SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LAB SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LARGE SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LARGE SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LARGE SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LARGE SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LARGE SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY LARGE SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PILOT SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PILOT SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PILOT SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PILOT SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PILOT SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY INSECT CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY INSECT CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY INSECT CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY INSECT CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY INSECT CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY INSECT CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MICROBIAL FERMENTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MICROBIAL FERMENTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MICROBIAL FERMENTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MICROBIAL FERMENTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MICROBIAL FERMENTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY MICROBIAL FERMENTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PLANT CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PLANT CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PLANT CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PLANT CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PLANT CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY PLANT CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL UPSTREAM BIOPROCESSING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA UPSTREAM BIOPROCESSING MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY MEDIA, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA UPSTREAM BIOPROCESSING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)

TABLE 30